Recombinant human GH replacement increases CD34+ cells and improves endothelial function in adults with GH deficiency

European Journal of Endocrinology

Volumn 159, Issue 2, 2008, Pages 105-111

  van der Klaauw, Agatha A ^a   Pereira, Alberto M ^a   Rabelink, Ton J ^a   Corssmit, Eleonora P M ^a   Zonneveld, Anton Jan ^a   Pijl, Hanno ^a   de Boer, Hetty C ^a   Smit, Johannes W A ^a   Romijn, Johannes A ^a   de Koning, Eelco J P ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; NITRIC OXIDE; SOMATOMEDIN C; CD34 ANTIGEN; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; AUGMENTATION INDEX; CD34 SELECTION; CELL COUNT; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MECHANISM; EVENING DOSAGE; FEMALE; FLOW CYTOMETRY; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS TUMOR; MALE; OPEN STUDY; PRIORITY JOURNAL; PULSE PRESSURE; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VASCULAR ENDOTHELIUM; VASODILATATION; BLOOD CELL; BLOOD CELL COUNT; DRUG EFFECT; HEMATOPOIETIC STEM CELL; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PITUITARY DWARFISM;

ADULT; AGED; ANTIGENS, CD34; BLOOD CELL COUNT; BLOOD CELLS; DWARFISM, PITUITARY; ENDOTHELIUM, VASCULAR; FEMALE; HEMATOPOIETIC STEM CELLS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 49649096650     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-08-0179     Document Type: Article

References (36)

1. de Boer H, Blok GJ & Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrine Reviews 1995 16 63-86.
2. van der Klaauw AA, Biermasz NR, Feskens EJ, Bos MB, Smit JW, Roelfsema F, Corssmit EP, Pijl H, Romijn JA & Pereira AM. The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. European Journal of Endocrinology 2007 156 455-462.
3. Elhadd TA, Abdu TA, Oxtoby J, Kennedy G, McLaren M, Neary R, Betch JJ & Clayton RN. Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. Journal of Clinical Endocrinology and Metabolism 2001 86 4223-4232.
4. Evans LM, Davies JS, Goodfellow J, Rees JA & Scanlon MF. Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clinical Endocrinology 1999 50 457-464.
5. Lanes R, Gunczler P, Lopez E, Esaa S, Villaroel O & Revel-Chion R. Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents. Journal of Clinical Endocrinology and Metabolism 2001 86 1061-1065.
6. Abdu TA, Elhadd TA, Buch H, Barton D, Neary R & Clayton RN. Recombinant GH replacement in hypopituitary adults improves endothelial cell function and reduces calculated absolute and relative coronary risk. Clinical Endocrinology 2004 61 387-393.
7. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B & Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. Journal of Clinical Endocrinology and Metabolism 2004 89 2192-2199.
8. Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P & Clayton RN. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 1999 84 453-457.
9. Smith JC, Evans LM, Wilkinson I, Goodfellow J, Cockcroft JR, Scanlon MF & Davies JS. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study Clinical Endocrinology 2002 56 493-501.
10. van der Klaauw AA, Romijn JA, Biermasz NR, Smit JW, van Doorn J, Dekkers OM, Roelfsema F & Pereira AM. Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. European Journal of Endocrinology 2006 155 701-708.
11. Rabelink TJ, de Boer HC, de Koning EJ & van Zonneveld AJ. Endothelial progenitor cells: more than an inflammatory response? Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 834-838.
12. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ & van Zonneveld AJ. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004 53 195-199.
13. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA & Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. New England Journal of Medicine 2003 348 593-600.
14. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M & Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. New England Journal of Medicine 2005 353 999-1007.
15. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT & Ingram DA. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007 109 1801-1809.
16. Urbich C & Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circulation Research 2004 95 343-353.
17. Fadini GP, de Kreutzenberg SV, Coracina A, Baesso I, Agostini C, Tiengo A & Avogaro A. Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. European Heart Journal 2006 27 2247-2255.
18. van Wijk JP, de Koning EJ, Cabezas MC, op't RJ, Joven J, Rabelink TJ & Hoepelman AI. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Annals of Internal Medicine 2005 143 337-346.
19. van Wijk JP, de Koning EJ, Cabezas MC, Joven J, op't RJ, Rabelink TJ & Hoepelman AM. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. Journal of the American College of Cardiology 2006 47 1117-1123.
20. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR & Webb DJ. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. Journal of Hypertension 1998 16 2079-2084.
21. Kelly R & Fitchett D. Noninvasive determination of aortic input impedance and external left ventricular power output: a validation and repeatability study of a new technique. Journal of the American College of Cardiology 1992 20 952-963.
22. Verbeke F, Segers P, Heireman S, Vanholder R, Verdonck P & Van Bortel LM. Noninvasive assessment of local pulse pressure: importance of brachial-to-radial pressure amplification. Hypertension 2005 46 244-248.
23. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC & Stewart PM. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001 357 425-431.
24. Rosen T & Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990 336 285-288.
25. Pfeifer M, Verhovec R & Zizek B. Growth hormone (GH) and atherosclerosis: changes in morphology and function of major arteries during GH treatment. Growth Hormone and IGF Research 1999 9 (Suppl A) 25-30.
26. Lanes R, Soros A, Flores K, Gunczler P, Carrillo E & Bandel J. Endothelial function, carotid artery intima-media thickness, epicardial adipose tissue, and left ventricular mass and function in growth hormone-deficient adolescents: apparent effects of growth hormone treatment on these parameters. Journal of Clinical Endocrinology and Metabolism 2005 90 3978-3982.
27. Thum T, Fleissner F, Klink I, Tsikas D, Jakob M, Bauersachs J & Stichtenoth DO. Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-1. Journal of Clinical Endocrinology and Metabolism 2007 92 4172-4179.
28. Carlo-Stella C, Di Nicola M, Milani R, Guidetti A, Magni M, Milanesi M, Longoni P, Matteucci P, Formelli F, Ravagnani F, Corradini P & Gianni AM. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. Blood 2004 103 3287-3295.
29. Evans LM, Davies JS, Anderson RA, Ellis GR, Jackson SK, Lewis MJ, Frenneaux MP, Rees A & Scanlon MF. The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. European Journal of Endocrinology 2000 142 254-262.
30. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC & Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney International 1994 45 598-604.
31. Boger RH, Skamira C, Bode-Boger SM, Brabant G, von zur MA & Frolich JC. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. Journal of Clinical Investigation 1996 98 2706-2713.
32. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM & Dimmeler S. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nature Medicine 2003 9 1370-1376.
33. Hanley MB, Napolitano LA & McCune JM. Growth hormone-induced stimulation of multilineage human hematopoiesis. Stem Cells 2005 23 1170-1179.
34. Merchav S. The haematopoietic effects of growth hormone and insulin-like growth factor-I. Journal of Pediatric Endocrinology and Metabolism 1998 11 677-685.
35. Chang KH, Chan-Ling T, McFarland EL, Afzal A, Pan H, Baxter LC, Shaw LC, Caballero S, Sengupta N, Li CS, Sullivan SM & Grant MB. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. PNAS 2007 104 10595-10600.
36. McCallum RW, Sainsbury CA, Spiers A, Dominiczak AF, Petrie JR, Sattar N & Connell JM. Growth hormone replacement reduces C-reactive protein and large-artery stiffness but does not alter endothelial function in patients with adult growth hormone deficiency. Clinical Endocrinology 2005 62 473-479.